Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

A recent report from Back Bay Life Science Advisors shows a surge in testing of, and investment in, multifunctional ...

Susan Monarez told Senators at a hearing Wednesday that Robert F. Kennedy Jr. pushed her out for refusing to rubber-stamp ...

The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there ...

Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...

Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from ...

Roche’s CEO claimed 89bio’s drug, which is in late-stage testing, has the potential to show “best-in-disease efficacy” for ...

New study data showed treatment slowed signs of disease progression by 75% after three years, a finding that could have ...

The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do ...

Thermal modeling uses heat transfer and fluid dynamics equations to estimate how temperature changes within a system over time. This simulation allows packaging designers to predict how a solution ...